SG11201807365QA - a-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - Google Patents
a-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOFInfo
- Publication number
- SG11201807365QA SG11201807365QA SG11201807365QA SG11201807365QA SG11201807365QA SG 11201807365Q A SG11201807365Q A SG 11201807365QA SG 11201807365Q A SG11201807365Q A SG 11201807365QA SG 11201807365Q A SG11201807365Q A SG 11201807365QA SG 11201807365Q A SG11201807365Q A SG 11201807365QA
- Authority
- SG
- Singapore
- Prior art keywords
- new york
- international
- brook
- stony
- stony brook
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/55—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/04—Saturated compounds having a carboxyl group bound to a three or four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307262P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021711 WO2017156354A1 (en) | 2016-03-11 | 2017-03-10 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807365QA true SG11201807365QA (en) | 2018-09-27 |
Family
ID=59789897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807365QA SG11201807365QA (en) | 2016-03-11 | 2017-03-10 | a-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| SG10202008700VA SG10202008700VA (en) | 2016-03-11 | 2017-03-10 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008700VA SG10202008700VA (en) | 2016-03-11 | 2017-03-10 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10968163B2 (enExample) |
| EP (1) | EP3452441B1 (enExample) |
| JP (1) | JP6976581B2 (enExample) |
| KR (1) | KR102365059B1 (enExample) |
| CN (1) | CN109415295B (enExample) |
| AU (1) | AU2017230790B2 (enExample) |
| BR (1) | BR112018068414B1 (enExample) |
| CA (1) | CA3017496A1 (enExample) |
| EA (1) | EA201892045A1 (enExample) |
| MX (1) | MX2018010801A (enExample) |
| SG (2) | SG11201807365QA (enExample) |
| WO (1) | WO2017156354A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9604904B2 (en) | 2012-07-20 | 2017-03-28 | The Research Foundation For The State University Of New York | Alpha- and gamma-truxillic acid derivatives and pharmaceutical compositions thereof |
| MX2018010801A (es) * | 2016-03-11 | 2019-02-07 | Univ New York State Res Found | Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos. |
| JP2023503613A (ja) * | 2019-11-25 | 2023-01-31 | ザ・リサーチ・ファウンデーション・フォア・ザ・ステイト・ユニバーシティー・オブ・ニューヨーク | 癌の処置のためにタキサンと共にfabp5阻害剤を使用する併用療法 |
| CN116615193A (zh) * | 2020-10-08 | 2023-08-18 | 纽约州立大学研究基金会 | 作为选择性fabp5抑制剂的吐昔酸单酯衍生物和药物组合物及其用途 |
| WO2025193881A1 (en) * | 2024-03-12 | 2025-09-18 | Artelo Biosciences Incorporated | Enantiomers that inhibit fatty acid binding protein 5 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
| JP2001199884A (ja) | 2000-01-21 | 2001-07-24 | Seiwa Yakuhin Kk | 鎮痛作用剤 |
| ES2189602B1 (es) | 2000-10-11 | 2004-08-01 | Universidad De Murcia | Procedimiento para la inmovilizacion de un ligando sobre un soporte. |
| JP2002154959A (ja) * | 2000-11-15 | 2002-05-28 | Seiwa Yakuhin Kk | 鎮痛抗炎症作用剤 |
| AU2002348276A1 (en) | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8980820B2 (en) | 2009-01-19 | 2015-03-17 | The Research Foundation For The State University Of New York | Fatty acid binding proteins as drug targets for endocannabinoids |
| CN101838239B (zh) | 2010-02-02 | 2012-03-21 | 中国科学院广州生物医药与健康研究院 | 一种吡唑类化合物及其组合物和应用 |
| US9604904B2 (en) * | 2012-07-20 | 2017-03-28 | The Research Foundation For The State University Of New York | Alpha- and gamma-truxillic acid derivatives and pharmaceutical compositions thereof |
| CA2878804A1 (en) * | 2012-09-12 | 2014-03-20 | F. Hoffmann-La Roche Ag | Non-annulated thiophenylamides as inhibitors of fatty acid binding protein(fabp) 4 and/or 5 |
| MX2018010801A (es) | 2016-03-11 | 2019-02-07 | Univ New York State Res Found | Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos. |
-
2017
- 2017-03-10 MX MX2018010801A patent/MX2018010801A/es unknown
- 2017-03-10 CA CA3017496A patent/CA3017496A1/en active Pending
- 2017-03-10 BR BR112018068414-7A patent/BR112018068414B1/pt active IP Right Grant
- 2017-03-10 US US16/080,493 patent/US10968163B2/en active Active
- 2017-03-10 EP EP17764162.8A patent/EP3452441B1/en active Active
- 2017-03-10 WO PCT/US2017/021711 patent/WO2017156354A1/en not_active Ceased
- 2017-03-10 SG SG11201807365QA patent/SG11201807365QA/en unknown
- 2017-03-10 SG SG10202008700VA patent/SG10202008700VA/en unknown
- 2017-03-10 EA EA201892045A patent/EA201892045A1/ru unknown
- 2017-03-10 JP JP2018567019A patent/JP6976581B2/ja active Active
- 2017-03-10 AU AU2017230790A patent/AU2017230790B2/en active Active
- 2017-03-10 CN CN201780016751.4A patent/CN109415295B/zh active Active
- 2017-03-10 KR KR1020187028746A patent/KR102365059B1/ko active Active
-
2021
- 2021-02-11 US US17/174,030 patent/US11739047B2/en active Active
-
2023
- 2023-07-03 US US18/346,363 patent/US20240092725A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017230790A1 (en) | 2018-11-01 |
| US20210179535A1 (en) | 2021-06-17 |
| EA201892045A1 (ru) | 2019-04-30 |
| EP3452441A1 (en) | 2019-03-13 |
| SG10202008700VA (en) | 2020-10-29 |
| JP6976581B2 (ja) | 2021-12-08 |
| CN109415295B (zh) | 2022-05-17 |
| US20190062261A1 (en) | 2019-02-28 |
| EP3452441A4 (en) | 2019-10-23 |
| BR112018068414B1 (pt) | 2022-08-23 |
| EP3452441B1 (en) | 2025-08-27 |
| JP2019510086A (ja) | 2019-04-11 |
| AU2017230790B2 (en) | 2021-07-08 |
| US11739047B2 (en) | 2023-08-29 |
| MX2018010801A (es) | 2019-02-07 |
| US20240092725A1 (en) | 2024-03-21 |
| CA3017496A1 (en) | 2017-09-14 |
| CN109415295A (zh) | 2019-03-01 |
| KR20180120230A (ko) | 2018-11-05 |
| US10968163B2 (en) | 2021-04-06 |
| WO2017156354A1 (en) | 2017-09-14 |
| NZ747067A (en) | 2025-02-28 |
| KR102365059B1 (ko) | 2022-02-18 |
| BR112018068414A2 (pt) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201900947RA (en) | Tlr7/8 antagonists and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201810611YA (en) | Coumarin compounds and their uses as fluorescent labels | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201807365QA (en) | a-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201903193WA (en) | Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate | |
| SG11201909263XA (en) | Improvements in or relating to organic compounds | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses |